BJT-678
/ Bluejay Therap
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
April 15, 2025
A study to evaluate the safety, tolerability, pharmacokinetics and antiviral activity of BJT-678 in subjects with chronic Hepatitis B Infection, including subjects with Chronic Hepatitis D infection
(ANZCTR)
- P1 | N=50 | Not yet recruiting | Sponsor: Bluejay Therapeutics, Inc
New P1 trial • Hepatitis B • Hepatology • Infectious Disease • Inflammation
1 to 1
Of
1
Go to page
1